163 related articles for article (PubMed ID: 7939418)
1. Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice.
Kim JK; Tsen MF; Ghetie V; Ward ES
Scand J Immunol; 1994 Oct; 40(4):457-65. PubMed ID: 7939418
[TBL] [Abstract][Full Text] [Related]
2. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor.
Kim JK; Tsen MF; Ghetie V; Ward ES
Eur J Immunol; 1994 Oct; 24(10):2429-34. PubMed ID: 7925571
[TBL] [Abstract][Full Text] [Related]
3. Evidence that the hinge region plays a role in maintaining serum levels of the murine IgG1 molecule.
Kim JK; Tsen MF; Ghetie V; Ward ES
Mol Immunol; 1995 May; 32(7):467-75. PubMed ID: 7783750
[TBL] [Abstract][Full Text] [Related]
4. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis.
Kim JK; Tsen MF; Ghetie V; Ward ES
Eur J Immunol; 1994 Mar; 24(3):542-8. PubMed ID: 8125126
[TBL] [Abstract][Full Text] [Related]
5. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn.
Popov S; Hubbard JG; Kim J; Ober B; Ghetie V; Ward ES
Mol Immunol; 1996 Apr; 33(6):521-30. PubMed ID: 8700168
[TBL] [Abstract][Full Text] [Related]
6. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.
Ghetie V; Hubbard JG; Kim JK; Tsen MF; Lee Y; Ward ES
Eur J Immunol; 1996 Mar; 26(3):690-6. PubMed ID: 8605939
[TBL] [Abstract][Full Text] [Related]
7. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1.
Medesan C; Matesoi D; Radu C; Ghetie V; Ward ES
J Immunol; 1997 Mar; 158(5):2211-7. PubMed ID: 9036967
[TBL] [Abstract][Full Text] [Related]
8. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
9. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
[TBL] [Abstract][Full Text] [Related]
10. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.
Canfield SM; Morrison SL
J Exp Med; 1991 Jun; 173(6):1483-91. PubMed ID: 1827828
[TBL] [Abstract][Full Text] [Related]
11. Localization of the site of the IgG molecule that regulates maternofetal transmission in mice.
Medesan C; Radu C; Kim JK; Ghetie V; Ward ES
Eur J Immunol; 1996 Oct; 26(10):2533-6. PubMed ID: 8898970
[TBL] [Abstract][Full Text] [Related]
12. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.
Wines BD; Powell MS; Parren PW; Barnes N; Hogarth PM
J Immunol; 2000 May; 164(10):5313-8. PubMed ID: 10799893
[TBL] [Abstract][Full Text] [Related]
13. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.
Kim JK; Firan M; Radu CG; Kim CH; Ghetie V; Ward ES
Eur J Immunol; 1999 Sep; 29(9):2819-25. PubMed ID: 10508256
[TBL] [Abstract][Full Text] [Related]
14. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.
Chappel MS; Isenman DE; Everett M; Xu YY; Dorrington KJ; Klein MH
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9036-40. PubMed ID: 1833770
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human lactoferrin-Fc fusion with an improved plasma half-life.
Shiga Y; Oshima Y; Kojima Y; Sugimoto A; Tamaki N; Murata D; Takeuchi T; Sato A
Eur J Pharm Sci; 2015 Jan; 67():136-143. PubMed ID: 25433245
[TBL] [Abstract][Full Text] [Related]
16. Improved Refolding of a Human IgG1 Fc (CH2-CH3) Scaffold from Its Inclusion Body in E. coli by Alkaline Solubilization.
Ishikawa S; Ishikawa H; Sato A
Biol Pharm Bull; 2022; 45(3):284-291. PubMed ID: 35228394
[TBL] [Abstract][Full Text] [Related]
17. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site.
Medesan C; Cianga P; Mummert M; Stanescu D; Ghetie V; Ward ES
Eur J Immunol; 1998 Jul; 28(7):2092-100. PubMed ID: 9692877
[TBL] [Abstract][Full Text] [Related]
19. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
[TBL] [Abstract][Full Text] [Related]
20. Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody.
Chappel MS; Isenman DE; Oomen R; Xu YY; Klein MH
J Biol Chem; 1993 Nov; 268(33):25124-31. PubMed ID: 8227075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
